QQ3 2024 for enGene is characterized by a pre-revenue profile typical of a clinical-stage biotechnology company. Revenue remains nil, while gross profit is negative by $0.082 million due to minimal cost of revenue. R&D expense far exceeds revenue at $11.549 million, complemented by G&A of $5.210 million and SG&A of $4.682 million, yielding total operating expenses of $16.759 million. The company reported an operating loss of $16.759 million and a net loss of $14.148 million ($0.32 per share) for the quarter. EBITDA stood at negative $13.344 million. Cash burn from operations was $7.181 million, with free cash flow of negative $7.183 million; however, ENGN ended the quarter with a strong liquidity position of approximately $257.7 million. Net debt remains negative by about $232.8 million due to excess cash versus debt, underpinning a multi-year runway to advance EG70 and other mucosal-delivery programs. While profitability is not imminent, the balance sheet provides substantial flexibility to fund ongoing clinical development and explore partnering opportunities to monetize the pipeline if milestones are achieved.
Given the absence of revenue and the ongoing emphasis on development milestones, the key drivers for investors will be the progress and readouts of EG70, any regulatory interactions, and potential strategic collaborations that could de-risk development and enhance value realization.